RxDoctor Payments Data
★ My doctorsLook up a doctor →

Jeffrey Geller, MD

Orthopaedic Surgery · New York, NYNPI 1083650758

Payments from drug & device makers

What this record shows

The money is spread across several categories — royalties or licence payments (55.0%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. Smith+Nephew accounts for 99.2% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $154,432, 2.0 times the $76,914 reported in 2019. Among orthopaedic surgery clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$586,308in general payments, 2019–2025

Across 253 payments — averaging $2317.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$582K
  • Zimmer Biomet$3K
  • Stryker$683
  • Johnson & Johnson$503
  • Medacta USA, Inc.$152
  • Heron Therapeutics, Inc.$135
  • plus $460 from 5 others
$47,494in research payments, 2019–2025

Across 16 payments — averaging $2968.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Smith+Nephew$29K
  • Orthosensor Inc.$18K

What the payments were for

  • Royalty or licence$322,18355%
  • Consulting fees$59,53810%
  • Speaking & faculty fees$175,38930%
  • Travel & lodging$20,2523%
  • Food & beverage$8,9012%
  • Education$470%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Smith+Nephew209$581,722
Zimmer Biomet19$2,653
Stryker6$683
Johnson & Johnson(2 entities)6$503
Medacta USA, Inc.2$152
Heron Therapeutics, Inc.2$135
KCI USA, Inc.2$125
Guard Medical Inc.2$124
Innovation Technologies Inc1$120
Amgen3$66
Vertex1$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$586,308 in reported general payments places this provider in the 95th percentile of 1,079 orthopaedic surgery providers in New York.

See all orthopaedic surgery providers in New York →

Medicare billing

Part B allowed, 2024
$699,174
Medicare patients
802
Services billed
3,077

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Celecoxib26$338
Meloxicam119$283
Oxycodone Hcl41$174
Tramadol Hcl38$100
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen11$70
Omeprazole11$63
Ibuprofen11$48
Amoxicillin25$44

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery in New York

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →